In conclusion, this first comprehensive analysis of Romanian ovarian cancer patients highlights the high prevalence of TP53 and BRCA1/2 alterations, as well as the distribution of genomic instability across histologic subtypes and clinical stages. This evidence concerns the gene TP53 and ovarian carcinoma.